Fresh analysis reveals that patients who come off popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass much more quickly than those who stop conventional lifestyle programs.
Research printed in a prominent medical journal points out that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight comes back at an average rate of 0.8 kg per month once they quit.
"People purchasing such medications need to be informed of the risk of fast weight regain when the medication concludes," warns lead investigator Dr. Susan Jebb.
Such speed of regain implies a return to starting mass in about one and a half years.
Weighing Therapies
The research, which examined dozens of trials involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
The team emphasize that people who lose weight through diet and exercise typically see a less rapid creep back—around 0.1 kg a month—post-intervention.
Explaining the Quick Rebound
Nutrition scientists believe the mechanism of the jabs explains the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which moderates appetite.
"Artificially providing GLP-1 concentrations several times higher than normal could lead to the body to produce less of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a dietetics expert.
"Withdrawal of this GLP-1 'fix' leads to hunger is no longer kept in check, making overeating much more probable."
A Chronic Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
Many experts say that, considering the high risk of weight regain, the therapy should be considered life-long.
This view is supported by drug manufacturers, who note that the findings "underscore the chronic character of obesity," akin to managing conditions like diabetes.
User Accounts
People who have come off the medication describe a powerful return of appetite.
"It was like something activating and I was suddenly starving," described a patient.
This difficulty is exacerbated if individuals have not established sustainable lifestyle or habit changes during treatment.
Significant Interest
Figures show that millions of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Use is more common among females than men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the medications through private healthcare rather than public health services.
Ultimately, experts stress that while these medications are potent tools for weight loss, they are not a magic solution and maintained weight loss relies on ongoing behavioural support.
